chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Feeling cold, Injection site erythema, Injection site pain
Clinical narrative: Site  arm redness, swelling, at site starting first evening after morning vaccine, progressively worse, making sleep difficult.  Chills 2nd day, fever 100F by evening 2nd day and in morning 3rd day, muscle aches and joint pain, 2nd day evening continued through 4th day, with injection site Arm pain still present on 5th day radiating pain into lower arm and fingers.  Most body aches discontinued.  Difficulty feeling warm on 5th day.  Used Advil to reduce fever and pain.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site swelling, Insomnia, Myalgia, Pain, Pain in extremity
Clinical narrative: Site  arm redness, swelling, at site starting first evening after morning vaccine, progressively worse, making sleep difficult.  Chills 2nd day, fever 100F by evening 2nd day and in morning 3rd day, muscle aches and joint pain, 2nd day evening continued through 4th day, with injection site Arm pain still present on 5th day radiating pain into lower arm and fingers.  Most body aches discontinued.  Difficulty feeling warm on 5th day.  Used Advil to reduce fever and pain.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Site  arm redness, swelling, at site starting first evening after morning vaccine, progressively worse, making sleep difficult.  Chills 2nd day, fever 100F by evening 2nd day and in morning 3rd day, muscle aches and joint pain, 2nd day evening continued through 4th day, with injection site Arm pain still present on 5th day radiating pain into lower arm and fingers.  Most body aches discontinued.  Difficulty feeling warm on 5th day.  Used Advil to reduce fever and pain.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Extra dose administered
Clinical narrative: administered booster of Moderna vaccine, however patient had already received a booster in August 2021
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: Extra dose administered, Urticaria
Clinical narrative: Two weeks after the booster I started getting hives on my legs . They started at night and would be gone by morning . However now says later they are coming and going all day and have also shown up on my back and arms . Hydrocortisone doesn't seem to help much . Allegra helped in the morning for a while .
Age: 31.0
Sex: M
Vaccine: COVID19
Symptoms: Chest pain, Dyspnoea, Headache, Migraine
Clinical narrative: The first few days after receiving the vaccine there were complications breathing, chest pains and having shortness of breath. I was also suffering from headaches. The chest pains have stopped along with the breathing issues but I have since been suffering from migraines on a daily basis.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Heavy menstrual bleeding, Ovulation pain
Clinical narrative: Extremely painful during ovulation and menstrual period. Also, heavier periods
Age: 40.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Extra dose administered, Joint range of motion decreased
Clinical narrative: Shoulder pain, lack of range of motion. Hurt immediately after booster dose went away and now 4 days later is back and far worse.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature increased, Chills, Injection site induration, Injection site pain, Injection site swelling
Clinical narrative: Thursday, 11/25/2021 Achy arm at shot site, but not as bad as 1st shot Small raised firm bump at shot site Mild cramps in morning Chills morning Progressive high temperature 102 by 5:00pm  Friday, 11/25/2021 Morning - mild cramps, temperature back to normal Under arm pit - achy Shot site - still achy and with heart shaped pink puffiness and hard at shot site 2:00pm - temperature 102 6:00pm - temperature normal
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle spasms
Clinical narrative: Thursday, 11/25/2021 Achy arm at shot site, but not as bad as 1st shot Small raised firm bump at shot site Mild cramps in morning Chills morning Progressive high temperature 102 by 5:00pm  Friday, 11/25/2021 Morning - mild cramps, temperature back to normal Under arm pit - achy Shot site - still achy and with heart shaped pink puffiness and hard at shot site 2:00pm - temperature 102 6:00pm - temperature normal
Sex: F
Vaccine: VARCEL, VARZOS
Symptoms: Inappropriate schedule of product administration, No adverse event
Clinical narrative: no additional AEs reported; Varivax and GFK Shringix received at the same time (a minimum of 8 weeks interval should be provided); Varivax and GFK Shringix received at the same time; This spontaneous report was received from a medical assistant and refers to a 50-year-old female patient. The patient's concurrent conditions, medical history and concomitant therapies were not provided.  On 26-OCT-2021, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) 0.5 ml subcutaneously, lot # T025944, expiration date 30-JUL-2021 and at the same time (also reported as at the same visit) with varicella zoster vaccine rge (cho)(SHINGRIX) 0.5 ml intramuscularly, lot # NX7NA (expiration date was not provided), both for prophylaxis (inappropriate schedule of drug administration, overdose). No adverse events were reported.
Sex: U
Vaccine: MMR
Symptoms: Expired product administered, No adverse event
Clinical narrative: no additional adverse events reported; patient was administered an expired vaccine today; This spontaneous report was received from a nurse and refers to a patient of unknown gender and age. The patient's concurrent conditions, medical history and concomitant therapies were not provided.  On 29-OCT-2021, the patient was vaccinated with a dose of expired measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live, recombinant human albumin (rHA) (M-M-R II) 1 dose, lot # S032826, expiration date 16-OCT-2021 (route of administration was not provided) for prophylaxis. No adverse events were reported.
Age: 37.0
Sex: M
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: no additional AE; patient was inadvertently administered a dose of VAQTA on 10/28/2021 with a labeled expiry of 10/25/2021; This spontaneous report was received from a medical assistant and refers to a 37-year-old male patient. No information regarding patient's pertinent medical history, drug reactions, allergies and concomitant medications.   On 28-OCT-2021, the patient was vaccinated with an expired dose of hepatitis a vaccine, inactivated (VAQTA) lot # T014589, expiration date 25-OCT-2021 for prophylaxis (exact dose, dose #, route and anatomical location were not provided).
Sex: U
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: No additional AE; received an expired VAQTA; This spontaneous report was received from a medical assistant concerning a patient of unknown age and gender. Information about the patient's concurrent conditions or medical history was not reported. Concomitant medications included an influenza vaccine (unspecified).  On 06-NOV-2021, the patient received 1 mL of an expired dose of hepatitis a vaccine, inactivated (VAQTA) (Expired product administered) (lot # T017179, expiration date 26-OCT-2021) for prophylaxis (dose number, route of administration, and anatomical location were not reported). It was reported that the vaccine did not have any temperature excursion. The medical assistant observed the patient, no additional adverse events were reported.
Sex: U
Vaccine: VARCEL
Symptoms: Product storage error
Clinical narrative: No other AE; temperature excursion; This spontaneous report was received from a nurse, referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, historical drugs, concurrent conditions, concomitant therapies, and previous drug reactions or allergies was not reported.   On 05-NOV-2021, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # U019905, expiration date 24-JUN-2023, at a dose of 0.5 milliliter for prophylaxis (vaccination scheme frequency, route of administration and anatomical site of vaccination were not reported).   The vaccine was stored in a temperature of 20 degree Fahrenheit for 17 (unspecified time unit). There was no previous temperature excursion reported.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No other AE; temperature excursion; This spontaneous report was received from a nurse, referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, historical drugs, concurrent conditions, concomitant therapies, and previous drug reactions or allergies was not reported.   On 05-NOV-2021, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # U019905, expiration date 24-JUN-2023, at a dose of 0.5 milliliter for prophylaxis (vaccination scheme frequency, route of administration and anatomical site of vaccination were not reported). No other adverse event reported.  The vaccine was stored in a temperature of 20 degree Fahrenheit for 17 (unspecified time unit). There was no previous temperature excursion reported.
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: No other AE; temperature excursion; This spontaneous report was received from a nurse, referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, historical drugs, concurrent conditions, concomitant therapies, and previous drug reactions or allergies was not reported.   On 05-NOV-2021, the patient was vaccinated with an improperly stored dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live, recombinant human albumin (rha) (PROQUAD) lot # U019289, expiration date 15-DEC-2022, at a dose of 0.5 milliliter for prophylaxis (vaccination scheme frequency, route of administration and anatomical site of vaccination were not reported). No other adverse event reported.  The vaccine was stored in a temperature of 20 degree Fahrenheit for 17 (unspecified time unit). There was no previous temperature excursion reported.
Sex: U
Vaccine: MMR
Symptoms: Incorrect route of product administration, No adverse event
Clinical narrative: No other adverse event occurred; First dose adminsitered intramuscularly on 10/15/2021. Second dose administered subcutaneously on 11/11/2021.; This spontaneous report as received from an other health professional refers to a patient of unknown age. The subject concurrent conditions, medical history, concomitant therapies were not reported.  On 15-OCT-2021, the patient was vaccinated with the first dose with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), intramuscular (IM), (Lot number: S036663, expiration number: 14-NOV-2021) for prophylaxis. (Experienced incorrect route of product administration). On 11-NOV-2021, the patient was vaccinated with the second dose with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II), subcutaneously (SC), (Lot number: S036663, expiration number: 14-NOV-2021) for prophylaxis. It was reported that, no adverse event (AE) occurred. At the time of the report, the outcome of the event was not reported.  The causal relationship between the event and the suspect vaccine was not reported.
Sex: U
Vaccine: MMR
Symptoms: Expired product administered, No adverse event
Clinical narrative: the vaccine was administered after expiration.; No adverse event; This spontaneous report as received from an other health professional (Nurse) referring to a patient of unknown age. The patient concomitant therapies, medical history, concurrent conditions, drug reactions and allergies were not reported.  On 15-NOV-2021, the patient was vaccinated with the first dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) (Lot # S036662, expiration date: 14-NOV-2021) 0.5 milliliter for prophylaxis (expired product administered). It was reported that no adverse event occurred. At the time of the report, the outcome of the event was not reported.  The causal relationship between the event and the suspect vaccine was not reported.
Sex: U
Vaccine: HIBV
Symptoms: Product storage error
Clinical narrative: no sign or symptom reported; temperature excursion; This spontaneous report was received from a registered nurse regarding a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported.      On 11-OCT-2021, a dose of haemophilus b conjugate vaccine (meningococcal protein conjugate)(LIQUID PEDVAXHIB) suffered a temperature excursion with a temperature of  9.7 celsius degrees for 1 hour. There was no previous temperature excursion. On 29-OCT-2021, the patient was vaccinated with that dose of haemophilus b conjugate vaccine (meningococcal protein conjugate)(LIQUID PEDVAXHIB), lot # T026961 with expiration date: 02-APR-2023, as prophylaxis (strength, dose and route of administration were not administered). There were no signs or symptoms reported.
Age: 0.33
Sex: M
Vaccine: MMRV
Symptoms: Adverse event, Aphasia, Carbohydrate intolerance, Coeliac disease, Dyspepsia
Clinical narrative: the patient had "multiple hospitalizations"; Celiac; seizure; cannot digest complex carbohydrates; loss of speech; This spontaneous report was received from a patient's mother and refers to a infant male patient of unknown age. He had none pertinent medical history and none drug reactions and allergies. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. The patient took no concomitant medications. On an unspecified date in March 2011, he was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection in arm for prophylaxis. On an unknown date in March 2011, 5 days later, the patient lost his speech. On an unspecified date in March 2011, he experienced a "permanent injury" as the patient cannot digest complex carbohydrates and unspecified adverse event due to which he sought medical attention and had multiple hospitalizations for an unknown duration. He remains on a strict diet as a treatment. On an unknown date, he had labs for celiac, electroencephalogram (EEG) to find out if he had a seizure, neurologist "did every panel he could think of", complete neurological work up and test for heterozygotes C677T performed. Results were not provided. The patient received vitamin A and cod liver oil as a treatment. The reporter was requesting to speak with a scientist regarding the ingredients in measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD), she wanted to know the exact ingredient that caused her sons reaction in order to determine if it is safe to give her son the Pfizer Covid vaccine for children. She threatened to hire lawyers if she can not speak with a scientist. The outcome of adverse event, seizure and coeliac was unknown. The outcome of carbohydrate intolerance was reported as not resolved. The outcome of loss of speech was reported as recovered. Relatedness between the events and suspect vaccine was not provided.  Upon internal review, the events of celiac and seizure were considered to be medically significant.
Age: 0.33
Sex: M
Vaccine: MMRV
Symptoms: Electroencephalogram, Injury, Laboratory test, Medical diet, Seizure
Clinical narrative: the patient had "multiple hospitalizations"; Celiac; seizure; cannot digest complex carbohydrates; loss of speech; This spontaneous report was received from a patient's mother and refers to a infant male patient of unknown age. He had none pertinent medical history and none drug reactions and allergies. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided. The patient took no concomitant medications. On an unspecified date in March 2011, he was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection in arm for prophylaxis. On an unknown date in March 2011, 5 days later, the patient lost his speech. On an unspecified date in March 2011, he experienced a "permanent injury" as the patient cannot digest complex carbohydrates and unspecified adverse event due to which he sought medical attention and had multiple hospitalizations for an unknown duration. He remains on a strict diet as a treatment. On an unknown date, he had labs for celiac, electroencephalogram (EEG) to find out if he had a seizure, neurologist "did every panel he could think of", complete neurological work up and test for heterozygotes C677T performed. Results were not provided. The patient received vitamin A and cod liver oil as a treatment. The reporter was requesting to speak with a scientist regarding the ingredients in measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD), she wanted to know the exact ingredient that caused her sons reaction in order to determine if it is safe to give her son the Pfizer Covid vaccine for children. She threatened to hire lawyers if she can not speak with a scientist. The outcome of adverse event, seizure and coeliac was unknown. The outcome of carbohydrate intolerance was reported as not resolved. The outcome of loss of speech was reported as recovered. Relatedness between the events and suspect vaccine was not provided.  Upon internal review, the events of celiac and seizure were considered to be medically significant.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional  reported; administered after temperature excursion; This spontaneous report was received from a nurse prescriber and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On an unknown date, the varicella virus vaccine live (oka/merck) (VARIVAX) lot # U008180 experienced the temperature excursion of possibly -11.6 degrees Celsius (C) for unknown time. The reporter was unsure of exact temperature and time. On 17-NOV-2021, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot # U008180 has been verified to be a valid lot number, expiration date was not reported, but upon internal validation established as 12-MAR-2023 (formulation, concentration, exact dose, dose number, route of administration and anatomical location were not reported) for prophylaxis (product storage error). There were no previous excursions reported. No adverse event was reported (no adverse event).
Sex: U
Vaccine: HPV9
Symptoms: Product storage error
Clinical narrative: no adverse event; GARDASIL 9 vaccine that underwent a temperature excursion was administered to a patient.; This spontaneous report as received from a registered nurse  refers to an identifiable patient of unknown age and gender.  The patient's medical history, concurrent conditions and concomitant therapies were not provided.   On 05-NOV-2021 the patient was vaccinated with a dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast)(GARDASIL 9)(unknown dosage; lot # T025369 expiration date: 01-DEC-2022 for prophylaxis) which underwent a temperature excursion. No adverse event was reported.
Age: 20.0
Sex: U
Vaccine: VARCEL
Symptoms: Expired product administered, No adverse event
Clinical narrative: caller reports no additionalat time of call; dose of VARlVAX with the labeled expiry 10/14/2021 was administered to a patient on 11/22/2021; This spontaneous report was received from a licensed practical nurse and refers to a 20-year-old patient of unknown age. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided.  On 22-NOV-2021, the patient was vaccinated with an expired dose of varicella virus vaccine live (Oka/Merck) (VARIVAX) 0.5 milliliter, lot # S032352, expiration date 14-OCT-2021 (route of administration and anatomical location were not provided) for prophylaxis. No additional adverse event was reported.
Sex: U
Vaccine: VARZOS
Symptoms: Leukaemia
Clinical narrative: leukemia cancer; This case was reported by a consumer via interactive digital media and described the occurrence of leukemia in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had shingles twice). Concurrent medical conditions included pain (had awful extreme pain and still had pain on and off).   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced leukemia (serious criteria GSK medically significant). On an unknown date, the outcome of the leukemia was unknown.   It was unknown if the reporter considered the leukemia to be related to Shingles vaccine.  Additional details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The patient could not get the shot and had the shingles twice, 1st time was not to bad and 2nd time was awful extremely pain and still had pain on and off. The patient had Shingles shot long time ago since then diagnosed with leukemia. The cancer physician would not let the patient had the shot. The patient was hoping, he/she did not get the shingles 3rd time. The follow up would not be possible as no contact details were available.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Rheumatoid arthritis, Vaccination failure
Clinical narrative: diagnosed with RA; after 2 starting doses, I got shingles/suspected vaccination failure; One of the side effects was shingles. Bad; This case was reported by a consumer via interactive digital media and described the occurrence of rheumatoid arthritis in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis and golimumab (Simponi Aria) for rheumatoid arthritis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine, the 1st dose of Shingles vaccine and Simponi Aria at an unknown dose and frequency. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced rheumatoid arthritis (serious criteria GSK medically significant), vaccination failure (serious criteria GSK medically significant) and shingles. The action taken with Simponi Aria was unknown. On an unknown date, the outcome of the rheumatoid arthritis, vaccination failure and shingles were unknown.   It was unknown if the reporter considered the rheumatoid arthritis, vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The patient took the shingles vaccine about 5 years ago from the date of reporting, was diagnosed with rheumatoid arthritis (RA), started taking Simponi Aria by infusion. The patient further stated that one of the side effects of it was shingles and the patient was thinking he/she would not get it because he had taken the vaccine. After 2 starting doses, he/she got shingles.  The patient said it was not a bad case, but bad enough. This case was considered as suspected vaccination failure as details regarding time to onset and laboratory confirmation were unknown at the time of reporting. It was unknown if the reporter considered the shingles to be related to Simponi Aria. No contact details were available.
Sex: U
Vaccine: VARZOS
Symptoms: Limb injury
Clinical narrative: damage shoulder for having jab; This case was reported by a consumer via interactive digital media and described the occurrence of shoulder injury in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced shoulder injury. On an unknown date, the outcome of the shoulder injury was unknown.   It was unknown if the reporter considered the shoulder injury to be related to Shingles vaccine.  Additional details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The patient damaged to his/her shoulder for having that Shingles jab and would never outweigh. The patient inquired what his/her immune system could have done, the patient so regret taking the shot, government push and hate that he/she caved to it. The follow up would not be possible as no contact details were available.
Sex: U
Vaccine: VARZOS
Symptoms: Herpes zoster, Vaccination failure
Clinical narrative: shots and I still break out with shingles/ suspected vaccination failure; shingles; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine and the 2nd dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant) and shingles. On an unknown date, the outcome of the vaccination failure and shingles were unknown.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine and Shingles vaccine.  Additional details were provided as follows: The case was self-reported by the patent. The age at vaccination was not reported. The reported stated that, he/she had the 2 Shingles shots and still broke out with shingles. The follow-up would not possible as no contact details were available. This case was considered as suspected vaccination failure as details regarding the laboratory test confirming shingles and time to onset for shingles were unknown at the time of reporting.
Sex: U
Vaccine: MNQ
Symptoms: Accidental overdose, Incorrect dose administered, Product preparation error
Clinical narrative: dose of Menveo, later received lyophilized menveo with Pfizer diluent/ received 1 dose of correct Menveo and 1 hr. later received the lyophilized menveo with Pfizer diluent; received lyophilized menveo with Pfizer diluent; received lyophilized menveo with Pfizer diluent; This case was reported by a other health professional via call center representative and described the occurrence of accidental overdose in a 12-year-old patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   Concomitant products included MENVEO.   On an unknown date, the patient received the 2nd dose of Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced accidental overdose, wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the accidental overdose, wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. The patient received 1 dose of correct Menveo and 1 hour later received the lyophilized menveo with Pfizer diluent, which led to accidental overdose. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021240689:same reporter US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021240689:same reporter US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021240689:Same reporter US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021240689:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021240689:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021240689:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021240689:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021240689:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243479:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021240689:Same reporter
Sex: U
Vaccine: MNQ
Symptoms: Incorrect dose administered, Product preparation error
Clinical narrative: received Menveo reconstituted with Pfizer Covid diluent; received Menveo reconstituted with Pfizer Covid diluent; This case was reported by a other health professional via call center representative and described the occurrence of wrong solution used in drug reconstitution in a patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA569A, expiry date unknown) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. On an unknown date, the outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Menveo lyophilized powder portion after being reconstituted with pfizer covid diluent when the patient was supposed to get the covid pfizer, which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. No reactions reported. The reporter consented to follow up. This case was linked with 12 linked cases reported by same reporter for different patients.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR243469:same reporter US-GLAXOSMITHKLINE-US2021AMR243478:Same reporter US-GLAXOSMITHKLINE-US2021AMR243472:Same reporter US-GLAXOSMITHKLINE-US2021AMR243477:Same reporter US-GLAXOSMITHKLINE-US2021AMR243469:Same reporter US-GLAXOSMITHKLINE-US2021AMR243475:Same reporter US-GLAXOSMITHKLINE-US2021AMR243473:Same reporter US-GLAXOSMITHKLINE-US2021AMR243476:Same reporter US-GLAXOSMITHKLINE-US2021AMR243474:Same reporter US-GLAXOSMITHKLINE-US2021AMR243470:Same reporter US-GLAXOSMITHKLINE-US2021AMR243480:Same reporter US-GLAXOSMITHKLINE-US2021240689:same reporter
Sex: U
Vaccine: VARZOS
Symptoms: COVID-19, Herpes zoster, Vaccination failure
Clinical narrative: had shingles, vaccine only lessons the breakouts/ Suspected vaccination failure; shingles; had covid; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had shingles about 20 times).   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and covid-19. On an unknown date, the outcome of the vaccination failure, shingles and covid-19 were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and covid-19 to be related to Shingles vaccine.  Additional details were provided as follows: The case was self-reported by the patient. The age at vaccination was unknown. The reporter stated that, the vaccine only lessened the breakouts. When he/she had covid it was the worst breakout ever. The follow-up would not possible as no contact details were available. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting.